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Abstract
Multiple sclerosis is an immune-mediated, demyelinating and neurodegenerative disease that currently lacks any
neuroprotective treatments. Innovative neuroprotective trial designs are required to hasten the translational process
of drug development. An ideal target to monitor the efficacy of strategies aimed at treating multiple sclerosis is the
visual system, which is the most accessible part of the human central nervous system. A novel C57BL/6 mouse line
was generated that expressed transgenes for a myelin oligodendrocyte glycoprotein-specific T cell receptor and a
retinal ganglion cell restricted-Thy1 promoter-controlled cyan fluorescent protein. This model develops spontaneous
or induced optic neuritis, in the absence of paralytic disease normally associated with most rodent autoimmune
models of multiple sclerosis. Demyelination and neurodegeneration could be monitored longitudinally in the living
animal using electrophysiology, visual sensitivity, confocal scanning laser ophthalmoscopy and optical coherence
tomography all of which are relevant to human trials. This model offers many advantages, from a 3Rs, economic and
scientific perspective, over classical experimental autoimmune encephalomyelitis models that are associated with
substantial suffering of animals. Optic neuritis in this model led to inflammatory damage of axons in the optic nerve
and subsequent loss of retinal ganglion cells in the retina. This was inhibited by the systemic administration of a
sodium channel blocker (oxcarbazepine) or intraocular treatment with siRNA targeting caspase-2. These novel
approaches have relevance to the future treatment of neurodegeneration of MS, which has so far evaded treatment.
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Introduction
Multiple sclerosis (MS) is an autoimmune, demyelinating
disease of the CNS, which is the major cause of non-traumatic
disability in young adults. MS is associated with immune-
mediated, relapsing-remitting disease [1], followed by or
replaced at onset by the development of progressive MS and
worsening of disability with or without superimposed relapses
[1]. Despite some success at treating relapsing MS with
immunosuppressive agents(Coles et al., 2008; Giovannoni et
al., 2010; Kappos et al., 2010), control of progressive disability
with neuroprotective therapies has yet to be achieved and
remains a significant unmet clinical need [1]. Progressive
disability is associated with the development of axonal and
neuronal loss mediated by immune-dependent and
independent mechanisms of neurodegeneration [2,3]. Whilst
the failure to control progression may be limited by the
identification of suitable modulatory agents, the most
appropriate trial to test therapeutic strategies has not been
defined [4]. Trials could take many years to complete because
of the significant pre-trial recruitment issues owing to the large
size of studies required, the long trial duration and the
substantial post-trial analysis. Therefore, alternative methods to
detect CNS damage and repair need to be developed and
evaluated.
The visual system is an accessible sensory system
incorporating white matter targeted by neuroinflammatory
disease and provides an ideal target to monitor nerve loss and
repair. Optic neuritis (ON) occurs as a result of inflammation of
the optic nerve and is often the presenting feature of MS [1].
This can result in loss of vision due to impulse conduction
failure through demyelination, axonal transection and loss in
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the optic nerve followed by depletion of retinal ganglion cells
(RGC) in the retina [5]. Whilst ON is associated with retinal
nerve fibre layer (RNFL) thinning during the progression of MS,
people with MS irrespective of a diagnosis of ON develop
retinal nerve loss [5]. Therefore, monitoring axonal loss due to
ON is a useful way to assess therapeutic strategies targeting
neurodegeneration during inflammatory CNS disease.
Experimental autoimmune encephalomyelitis (EAE) is the
most intensively used animal model for the study of
autoimmune CNS disease. EAE has contributed significantly to
our understanding of CNS biology, notably autoimmunity, and
has led to the development of several licensed therapies for the
treatment of relapsing MS [6,7]. Disease in EAE is associated
with a T cell-mediated, ascending paralysis of the tail and
hindlimbs [8] and is considered a substantial/severe procedure,
owing to the nature of induction with Freund’s adjuvant and the
clinical course resulting in suffering to the animal. It is clear that
immunosuppression can inhibit relapsing autoimmunity [3,7],
however, EAE can also exhibit immune-dependent and
autoimmune-independent progression associated with
neurodegeneration that may be relevant to progressive MS
[3,8,9]. EAE typically affects the spinal cord and although the
brain and optic nerves can be involved, optic neuritis is not
always a consistent feature [8,10]. However, when present,
labelling of RGC by retrograde uptake following surgical brain
injection of tracers, it is possible to detect RGC loss, secondary
to axonal damage [11].
We therefore aimed to create a novel mouse model of ON to
test neuroprotective strategies targeting MS and other
inflammatory optic neuropathies. An important additional aim
was to develop an alternative model to EAE and therefore
refine and reduce the number of animals used in research (3Rs
- refinement, reduction and replacement) over conventional
models that could be used to serially monitor immune-mediated
neurodegeneration, using outcome measures relevant to
human disease.
Materials & Methods
Animals
C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch(MOGTCR) mice [12]
andC57BL/6.Cg-Tg(Thy1-CFP)23Jrs/JThy1CFP mice [13] were
obtained from Jackson Laboratories (Bar Habor, Maine USA).
These were crossed to create a transgenic MOGTCRxThy1CFP
line (C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch.Cg-Tg(Thy1-
CFP)23Jrs/J) mouse. Animals were maintained in enriched
cages on a 12h:12h light:dark cycle with food and water ad
libitum, as reported previously to conform with the principles of
ARRIVE guidlelines [8]. It is known that environment can
influence spontaneous disease in T cell receptor transgenic
mice [14] and the mice used in this study were housed in
pathogen free individually ventilated cages and both male and
female animals from 8 weeks old were used in experiments. In
accordance with the Animals Act 1986, the procedures were
approved by a local, independent ethical committee (Queen
Mary University London Ethical Review Panel) and by the UK
Government Home Office Inspector. All procedures and
housing of animals were performed and controlled under
license of the researcher, the project and the Institution issued
by the UK Government. The housing/conditions cage sizes and
operating procedures are detailed in the reference provided [8],
we suggest replication of the model should be achieved in
similar conditions.
Animal phenotyping and genotyping
A quantitative PCR (qPCR) method was developed to
identify homozygous mice for breeding. The CFP
oligonucleotide sequence was identified from the NCBI
Nucleotide library and the MOGTCR transgene was sequenced
from PCR products. A duplex qPCR was performed with
Ribosomal protein S29 (RPS29) as an endogenous control,
which is expressed at a constant level [15]. Oligonucleotide
primers and probes based upon enhanced CFP (eCFP) (eCFP
forward primer, GCCTACATACCTCGCTCTGC; eCFP reverse
primer, CAACCCGGTAAGACACGACT; eCFP probe [FAM]-
ATCCTGTTACCAGTGGCTGC-[TAM]), MOGTCR (MOGTCR
forward primer, ACCCAGTGGTTCAAGGAGTG; MOGTCR
reverse primer, CTTGGTTCCCTGTCCAAAGA; MOGTCR probe
[FAM]-AGCGACTGGGCTGTGTACTT-[TAM]) and RPS29
(RPS29 forward primer, ACGGTCTGATCCGCAAATAC;
RPS29 reverse primer CATTCAAGGTCGCTTAGTCCA;
RPS29 probe [HEX]-TACGCGAAGGACATAGGCTT-[TAM])
were used in qPCR. The target gene probes were made with
the fluorescent dye FAM attached to the 5’ end and a
fluorescent quencher TAMRA attached to the 3’ end. The
reference gene probes were made with HEX attached to the 5’
end to allow distinction between target and reference gene.
Data was collected on 7500 System Sequence Detection
Software (Applied Biosystems, Warrington, Cheshire, UK) and
cycle threshold (Ct) values were analysed by using a manual
baseline of 0.2. Results were exported and analysed using
CopyCaller™ software to determine number of transgenes.
Induction of ON
Animals were injected intraperitoneally (i.p.) on day 0 and 2
with 150ng Bordetella pertussis toxin (PTX Sigma, Poole, UK)
and on day 14 with 0.25mg MOG-specific Z12 mouse IgG2a
monoclonal antibody, which was protein-G (GE Healthcare Life
Sciences, Buckinghamshire, UK) purified from tissue culture
supernatant or supplied by Dr. P. Smith, UK [16]. Bordetella
pertussis toxin is required to induce consistent disease, as
show previously in single MOGTCR transgenic mice [17].
Animals were monitored daily to assess the development of
paralysis, typical of EAE. These were scored 0= normal, 1 =
limp tail, 2 = impaired righting reflex, 3= hindlimb paresis, 4 =
complete hindlimb paralysis, 5= moribund [8]. Animals were
killed either by cervical cord dislocation of C02 overdose.
Anaesthesia
Animals were anaesthetised with an i.p. injection of 75mg/kg
ketamine and 1mg/kg medetomidine in normal saline and
reversal was achieved with 1mg/kg atipamezole. Eyes were
dilated with one drop of tropicamide (Minims® tropicamide 1%
w/v) and one drop of phenylephrine hydrochloride (Minims®
phenylephrine hydrochloride 2.5% w/v). A drop of 2%
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hydroxypropyl methylcellulose was used to prevent cataract
formation during anaesthesia.
Measurement of visual sensitivity
Visual sensitivity was measured using a visual-tracking
drum, which consisted of a motorised drum with black and
white vertical stripes, which rotated in a clockwise and anti-
clockwise direction at a frequency of 0.5 cycles/degree [18].
The mouse was placed on a stationary platform in the centre of
the drum and was not restrained allowing freedom of
movement. An initial settling period of 30 seconds was followed
by a pattern of 60 second clockwise rotations, a 30 second
intermediary pause and 60 second anti-clock wise rotations,
repeated twice. Successful ‘head tracking’ movement was
characterised as a horizontal head movement in the direction
of rotation at the same speed as the visual tracking drum.
Analysis of head tracking movements was performed blinded
by analysis of video recordings.
Measurement of visual evoked potential (VEP)
Anaesthetised animals were secured in a stereotaxic frame
and body temperature was maintained at 35°C with a small
heating plate with built-in resistance temperature detector
sensor connected to a direct current temperature controller.
Animals were dark adapted for 30 minutes and remained in the
dark between flashes. The active electrode was a needle
electrode placed subcutaneously (s.c.) over the visual cortex
and the reference electrode was a needle electrode placed s.c.
in the snout. The signal was amplified 10,000x (NL104A AC
Amplifier, Digitimer, UK) and a flash stimulus of 10ms duration
every 300ms from a stand-alone monocular ganzfield photic
stimulator (MGS-2, LKC Technologies, MD, USA) was
presented approximately 20cm from eyes at a flash intensity of
-10dB (0.2436cd.sec/m2). Signals were band pass filtered at
5Hz and 1kHz and sampled at 1000 Hz. Recordings were
made with Signal v3.11 and for each recording 200 stimuli
were captured and consecutive sweeps averaged to produce a
mean VEP response. Latency was measured between N1 and
P2 (ms) and amplitude was measured between N1 and P2
(μV).
Measurement of RGC loss using scanning laser
ophthalmoscope (SLO) and RNFL thinning using
optical coherence tomography (OCT)
A Multiline OCT was modified from a Spectralis® HRA +
OCT (Heidelberg Engineering, Heidelberg, Germany) to
comply with mouse optics. Modifications included a reduction in
the diameter of the excitation laser beam to 2mm to allow more
efficient coupling of laser light into the small aperture of the
mouse eye and addition of a +25 diopter add-on lens to correct
for the characteristic hyperopia in mice (Heidelberg
Engineering). In addition, the standard chin rest was replaced
with a special custom-built (Institute of Ophthalmology
workshop, London, UK) animal mount to allow the animal to be
positioned correctly. To allow visualisation of CFP-expressing
RGC (460nm excitation and 490nm detection) a RazorEdge®
ultrasteep long-pass filter, which transmitted between 458 and
670nm (LP02-458RS-25, Semrock, Baltimore, USA) was
inserted into a filter slot to allow detection of CFP.
Examinations were recorded in both right (oculus dextrus,
OD) and left eyes (oculus sinister, OS) of each animal at day 0
and day 21 after immunisation. To capture an OCT image,
animals were anaesthetised and placed on the animal mount
and an infra-red (IR) reflection image with the optic nerve head
in a centralised position was achieved with optimal focus
(approx +18.0 dioptres). A RNFL single exam using the
automatic real time (ART) mode (allows averaging of 100
recordings) was produced for each mouse eye, which
automatically measured RNFL thickness (µm) in a 30° circle
surrounding the optic nerve head. To capture an SLO image,
an IR reflection image was achieved as described previously
and the CFP (450nm) laser was selected to allow CFP-
expressing RGC to be visualised. A constant sensitivity of 80%,
a field view of 30° and a reference arm parameter of 28616µm
[28.616mm] were maintained for each eye examined. To
calculate the RGC density, images were analysed in a blinded
fashion using Image J software. Assumptions on the area of
retina observed were made from [19], who estimated 1° of field
is subtended by 30µm of retina, therefore, a 30° field of view is
subtended by 900µm area of retina. The numbers of RGC were
counted in the superior, nasal, inferior and temporal quadrants
and the total density of RGC calculated per mm2. It has been
shown that 95% of retinal CFP positive cells are RCG [20].
Whilst amacrine cells are labelled with CFP, these are found in
a different layer of the retina and are therefore not visualized
when viewing RGC.
Histological assessment
Animals were transcardially perfused with phosphate
buffered saline (PBS) and Karnovsky’s fixative. Tissue was
post-fixed using 1% aqueous (w/v) osmium tetroxide and was
resin embedded. Semi-thin sections were cut at 0.7µm
thickness and ultra-thin sections were cut between 80-90nm
with a 6mm Ultradiamond knife. Semi-thin sections were
stained with 1% toluidine blue and ultra-thin sections were
stained with Reynold’s Lead Citrate [10]. Samples were viewed
on a Nikon Eclipse 80i microscope and JEOL1010
transmission electron microscope.
Preparation of retinal flatmounts
Eyes were enucleated and immersed in 4% PFA (Sigma,
Poole, Dorset, UK) in PBS (pH7.4) overnight. The retinae were
dissected and the cornea, sclera, lens, hyaloid vasculature and
connective tissue were removed. Four radial incisions were cut
around the retinae and flatmounts were mounted onto slides
and cover slipped with anti-fade glycerol (CitiFluor Ltd, London,
UK). The retinal flatmounts were imaged by fluorescent
microscopy and RGC density was calculated by counting CFP
expressing RGC using Stereo Investigator 7.35.1. RGC were
counted by drawing a contour at 10x magnification around the
retinal nerve flatmount. A grid was created and a fractionator
probe was used to create 10 random counting frames (100µm
x 100µm). RGCs were counted at 40x magnification in each
randomly selected 100µm2 box. The total numbers of RGC was
calculated from the sample of 10 squares and an
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approximation of the density in the retinal flatmount was
calculated. The quanitification was carried out blinded to the
observer.
Immunohistochemistry
Frozen sections were thawed for 30 minutes at room
temperature and then immunostained for active caspase-2
using a 1:200 dilution rabbit polyclonal IgG (ab2251 - Abcam,
Cambridge, UK) and total caspase-2 using a 1:400 dilution
rabbit polyclonal IgG (sc-623 Santa Cruz), with a secondary
antibody Alexa Fluor 568 donkey anti-rabbit IgG (H+L) at a
1:1000 dilution (A-21206. Invitrogen, Paisley, UK). Sections
were imaged using a Zeiss LSM 510 confocal laser scanning
microscope [21].
Neuroprotective study of oxcarbazepine
Oxcarbazepine (OXC) (Sigma-Aldrich Ltd, Poole, Dorset,
UK) was administered in a 1:1 dilution of PBS and DMSO
(dimethyl sulfoxide) and administered i.p. daily in 100µl at a
dose of 10mg/kg. This drug dose was chosen based on those
used in other neuroprotection studies. Animals treated with
vehicle were injected i.p. daily with 100µl of 1:1 dilution of PBS
and DMSO. Analysis was performed blinded to treatment.
Animals were randomized to either treatment or drug within a
cage. The primary outcome was number of RGC in retinal
flatmounts as this was undertaken before acquisition of the
OCT/SLO device.
Intravitreal injection caspase-2 siRNA
Small interfering RNA (siRNA) targeting caspase-2 and
control nonsense siRNA were provided by Quark
Pharmaceuticals, California, USA as described previously [20].
A fine tip glass pipette was used to inject a total of 2μg of
caspase-2 siRNA dissolved in 2μl of physiological saline into
the mouse eye. The mouse was briefly anaesthetised in an
isofluorane chamber until eye flick response had stopped and
the mouse showed signs of slowed breathing. Animals were
intravitreally injected through the sclera immediately posterior
to the limbus in both eyes on day 0 and 10 after ON disease
(siRNA) induction. Analysis was performed blinded to
treatment.
Statistical Analysis
Statistical analysis was performed using SigmaStat 3.1.
Results were presented as mean values ± SEM. Differences
between outcome measures (visual sensitivity, VEP amplitude
and latency, OCT and SLO) for day 0 (before ON) and day 21
(after ON) were analysed using a paired t-test. Correlations
were analysed using the Pearson product moment correlation.
Results was considered significantly different if the probability
level P<0.05 (*), P<0.01(**) or P<0.001(***) was reached
between groups.
Results
Characterisation of MOGTCRxThy1CFP mouse model
H2-Ab-restricted, myelin oligodendrocyte glycoprotein
(MOG)-specific TCR transgenic C57BL/6-
Tg(Tcra2D2,Tcrb2D2)1Kuch (MOGTCR) mice (which has
previously been described and characterised [17]), were
crossbred with C57BL/6.Cg-Tg(Thy1-CFP)23Jrs/J (Thy1CFP)
transgenic mice that expressed neuronally-restricted,
Thy1(CD90)-promoter driven expression of CFP [13]. This
created a double transgenic MOGTCRxThy1CFP mouse, which
can develop spontaneous, and induced ON and express CFP
in the RGC. Approximately 30% of the MOGTCRxThy1CFP mice
develop spontaneous histological ON with a wide range of time
to onset (from 2.5 months to 5 months) consistent with that
reported previously for MOGTCR mice [12]. Therefore, an
immunising or induction protocol was developed to produce
high disease incidence and augment the demyelination
potential. Consistent with that reported previously [11,17]
spontaneous disease occurred in about 5% of animals and the
incidence of optic neuritis was increased following induction
with Bordetella pertussis toxin [11,17]. Animals were
immunised with Bordetella pertussis toxin to induce ON and
blood:optic nerve barrier dysfunction and then Z12 MOG-
specific demyelinating monoclonal antibody (mAb) [16,22]was
administered. Although the intention here was to induce ON in
the absence of paralytic EAE, it was possible to induce
classical paralytic EAE in these animals through administration
of additional doses of MOG-specific demyelinating mAb
through augmentation of sub-clinical spinal cord lesions (see
Table S1) or using active immunisation of MOG-peptide in
Freund’s adjuvant [17], should the researcher wish to use this
clinical outcome. This mAb treatment also augments classical
EAE, often to lethal disease [22]. However, through titration of
the amount of MOG-specific mAb, it was possible to induce a
milder disease with high incidence without paralytic disease,
which carried additional animal welfare benefits. The optic
nerve of wild type mice showed normal appearance of large
numbers of axons (Figure 1A) that were well myelinated
(Figure 1B). However, with the development of ON in
MOGTCRxThy1CFP mice, fewer numbers of axons were present
in affected optic nerves (Figure 1C) with evidence of
demyelinated axons (Figure 1D). Although demyelination was
present, this was not quantitated in the present study. Using
histology, the presence of glial processes within demyelinated,
particularly small diameter axons, make the assessment of
demyelination very difficult. A 33±18% loss of axons from the
optic was associated with a 25±8% loss of retinal ganglion cells
assessed in sections of the eye. However, demyelination as
assessed by increased latency in electrophysiological readings
made some form of quantitation possible and was reported.
Further studies are required to improve the amount of
demyelination with axonal preservation as loss of myelin is
associated with rapid axonal loss, as occurs in classical EAE
[6]. A uniform appearance of RGC were present in the ganglion
cell layer of the retina in wild type mice (Figure 1E), while ON in
mice resulted in significant (P<0.005) RGC loss (Figure 1F).
This represented about a 35% loss in RGC density (Figure 2A),
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quantified from retinal flatmounts in healthy controls (Figure
2B) compared to MOGTCRxThy1CFP (Figure 2C) mice. It was
possible to induce non-paralytic, neuroinflammatory disease in
the absence of Freund’s adjuvant and the loss in RGC number
could be detected without the need for surgical labelling
through injections of tracers into the brain. Having established
a method for induction of disease, the application of non-
invasive, quantitative outcome measures were investigated,
that would contrast the non-parametric and non-linear
neurological paralysis scales used in classical EAE [8].
Development of non-invasive methods of disease
assessment
Visual-tracking drum.  A visual-tracking/optokinetic drum
can be used to examine visual sensitivity by measuring positive
head movements in response to visual stimulation, provided by
a vertical bar on the rotating drum. This test assessed bi-lateral
vision and was not adjusted to detect the vision in individual
eyes [17]. Visual sensitivity was assessed in
MOGTCRxThy1CFP mice on day 0 (before disease onset) and
day 21 (after disease onset), using blinded assessment of
video recordings of head movements in relation to the direction
of the rotating drum. A significant reduction (P<0.01) in the
number of positive head movements was observed between
day 0 and day 21 (Figure 3A), with a lower incidence of positive
head movements occurring on day 21. These results show a
decrease in visual sensitivity following the development of ON
in MOGTCRxThy1CFP mice, indicating functional vision loss.
Electrophysiology.  Electrophysiology can be used to
examine changes in electrophysiological function of the optic
nerve by measuring visually evoked potentials (VEP) in
response to a flash stimulus. The VEP response was
measured in anaesthetised, MOGTCRxThy1CFP animals on day
0 (before disease onset) and day 21 (after disease onset) and
VEP recorded at a flash intensity of -10dB to assess changes
occurring through the development of ON. Recording from the
scalp immediately above the occipital lobe, with a reference
electrode at the snout, the typical VEP waveform recorded
consisted of a small positive peak (P1), a large negative peak
(N1) followed by a large positive peak (P2) (Figure 3B). VEP
recordings showed a significant decrease (P=0.040) in mean
amplitude between day 0 and day 21 with a 42% reduction in
mean amplitude (Figure 3C). A significant 28% increase
(P=0.049) in mean latency between day 0 and day 21 was
observed (Figure 3D). These results demonstrate that the
electrophysiological function of the optic nerve is dysfunctional
at day 21 due to disease activity resulting in reduced amplitude
and increased latency, correlating with axonal loss and
demyelination in the optic nerve, respectively.
Optical coherence tomography.  Optical coherence
tomography (OCT) is used in MS and other diseases to detect
RGC loss by measuring changes in the thickness of the retinal
nerve fibre layer (RNFL) [23,24]. Initial studies using
histological examination of retinal sections at the level of the
optic nerve head demonstrated that significant loss of RGC
occurred and that there was retinal thinning (Figure 4A). A
clinical OCT machine with a resolution of less than 3 μm
(Spectralis® HRA + OCT, Heidelberg Instruments, Germany),
modified to facilitate imaging of rodent eyes was obtained
during the course of this study (Figure 4B). Examination by
OCT in MOGTCRxThy1CFP animals on day 0 (before disease
onset) and day 21 (after disease onset) was used to analyse
the impact of disease on the reduction of RNFL thickness as a
result of RGC loss. The thickness of the RNFL in a defined
circle surrounding the optic nerve head was measured (Figure
4C). RNFL thickness at day 0 (Figure 4D) decreased by 12μm
after ON in MOGTCRxThy1CFP animals (Figure 4E),
representing a 32% decrease in RNFL thickness (Figure 4E
and F). The thickness of RNFL positively correlated with the
density of RGC in retinal flat mounts (Figure 4G) and thus
further validates the use of OCT as a surrogate outcome to
detect nerve loss in real-time.
Confocal scanning laser ophthalmoscope.  Whilst studies
in humans rely on OCT imaging, because of the CFP
transgene in MOGTCRxThy1CFP mice, it is possible to non-
invasively image individual nerves within the eye using a
confocal scanning laser ophthalmoscope (cSLO) to produce
high-quality magnified images [18]. Animals were
anaesthetised to obtain high quality images that were centred
around the optic nerve head. The cSLO was used to take
images of the retina of MOGTCRxThy1CFP on day 0 (Fig. 5A)
and day 21 (Fig. 5B), which allowed RGC density to be
quantified before and after disease induction (Fig.5C) and
compared to conventional histological assessment (retinal
flatmounts) of RGC loss. The density of RGC assessed by
cSLO was significantly reduced at day 21 compared to day 0
(P<0.037). The density of RGC detected by cSLO at day 21
(935±193 cells/mm2) correlated well with that determined by
histology (792±173 cells/mm2) and therefore suggests that the
use of cSLO to quantify RGC loss appears to be an accurate
method, agreeing with results obtained from histological
methods used previously. Using a 15° field of view, the cSLO
can also be used to detect individual RGC and areas of RGC
loss in the same mouse by using the topography of the blood
vessels to locate RGC at day 0 (Figure 5D) and at day 21
(Figure 5E). The results acquired using OCT and cSLO to
study the level of RGC loss in MOGTCRxThy1CFP mice are
concurrent; the decrease in the thickness of the RNFL using
OCT was 32±10% and the decrease in RGC density using
cSLO was 29±10%. These results provide further evidence that
measuring RGC loss using cSLO and RNFL thinning using
OCT are accurate methods to assess the disease process.
Therapeutic control of MOGTCRxThy1CFP: use as a
neuroprotective model
To validate the MOGTCRxThy1CFP model as a useful model
to detect and manipulate neuroinflammatory disease two
approaches using novel reagents were used. This involved the
systemic and local delivery of agents. Whilst there are an
increasing number of immunosuppressive agents that can
inhibit the relapsing component of MS, none have been shown
to control the neurodegenerative aspects of progressive MS
[1,25].
Systemic delivery of a neuroprotective agent.  It has been
suggested that mitochondrial dysfunction due to low grade
inflammation can lead to sodium loading and the triggering of
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Figure 1.  Optic and retinal nerve loss during ON in MOGTCRxThy1CFP mice.  (A) Semi-thin toluidine blue stained optic nerve
cross section and (B) ultra-thin lead citrate stained sections from wildtype mice showing uniformly myelinated axons (M). (C) Semi-
thin toluidine blue stained section and (D) ultra-thin lead citrate stained section of optic nerves from immunized MOGTCRxThy1CFP
developing ON on day 21, showing evidence of demyelination (D) and areas of axonal loss (AL). (E) Semi-thin toluidine blue stained
cross section of retina from wildtype mouse, showing healthy RGC (RGC) and (F) semi-thin toluidine blue stained cross section of
retina from immunised MOGTCRxThy1CFP mice developing ON on day 21 showing irregular RGC.
doi: 10.1371/journal.pone.0079188.g001
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death effector pathways leading to nerve death [26,27]. To
explore this potential we used the sodium channel blocker
Oxcarbazepine (OXC) (10,11-Dihydro-10-oxo-5h-
dibenz[b,f]azepine-5-carboxamide). Following the development
of neuroinflammatory disease treatment with 10mg/kg/day
OXC resulted in significant sparing of RGC compared to
treatment with vehicle (Figure 6A). The density of RGC was
significantly higher (P<0.05) following OXC treatment, with a
RGC density of 1398±9cells/mm2, compared to
1080±100cells/mm2 in the vehicle group. Therefore, OXC
showed the potential to increase the survival of RGC and
encouraging neuroprotective potential in the MOGTCRxThy1CFP
model.
Local Delivery of a neuroprotective agent.  The eye is a
CNS structure that is uniquely accessible to local treatment; we
therefore assessed this approach using a novel siRNA.
Caspases are death effector molecules that can trigger nerve
death in EAE [20]. Caspase-2 was found to be expressed and
cleaved (activated) in >95% of RGC after optic nerve crush
injury [20]. Immunohistochemistry to detect the expressed
caspase-2 (using an antibody against the propeptide of
caspase 2) and the cleaved activated caspase-2 (using an
antibody against the carboxyterminals aspartate D316 on
Figure 2.  RGC loss during ON in MOGTCRxThy1CFP mice.  (A) Decrease in mean RGC density after immunisation of
MOGTCRxThy1CFP mice (n=7) compared to control mice (n=7) at day 21. (B) Retinal flatmount of control mouse at 20x magnification
showing a high density of CFP expressing RGC and (C) retinal flatmount of retina after immunisation of MOGTCRxThy1CFP mice
showing a low density of CFP expressing RGC.
doi: 10.1371/journal.pone.0079188.g002
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activated caspase-2) demonstrated that expressed and active
caspase-2 was present in the RNFL and in particular, in axons
and cell bodies of RGC in MOGTCRxThy1CFP mice after ON
(Figure 6B and C). This indicated that casapase-2 may play a
role in the apoptotic pathway of RGC degeneration in the
MOGTCRxThy1CFP model of disease. The presence of
caspase-2 has previously been shown to be downregulated by
intravitreal injection of a chemically modified synthetic siRNA,
persists and acts locally within the eye for over 30 days [20].
Analysis of the RNFL thickness using OCT demonstrated a
significant inhibition of nerve cell loss following caspase-2
siRNA administration (Figure 6D). Both control and vehicle
groups showed a significant decrease in RNFL thickness,
21±6% and 27±7% respectively, after induction of ON as
measured at day 0 and day 21. Caspase-2 siRNA treatment
inhibited the decrease in RNFL thickness and showed a
negligible decrease of 3% compared to pre-disease levels.
Treatment with capase-2 siRNA had a significant effect on the
Figure 3.  Visual sensitivity loss and electrophysiological changes during ON in MOGTCRxThy1CFP mice.  (A) Decrease in
visual sensitivity after immunisation of MOGTCRxThy1CFP to develop ON (n=10). Results represent the mean ± SEM of net positive
head movements. **P<0.01 compared to control. (B) Typical waveform VEP showing P1 (first positive peak), N1 (first negative
peak), P2 (second positive peak). (C) Decrease in mean VEP amplitude after immunisation of MOGTCRxThy1CFP mice to develop
ON (n=5). (D) Increase in mean N1-P2 latency of VEP amplitude after immunisation of MOGTCRxThy1CFP mice to develop ON
(n=5). Results represent the mean ± SEM of amplitude. *P<0.05 compared to control.
doi: 10.1371/journal.pone.0079188.g003
Novel Mouse Model of Multiple Sclerosis
PLOS ONE | www.plosone.org 8 November 2013 | Volume 8 | Issue 11 | e79188
Figure 4.  OCT imaging during ON in MOGTCRxThy1CFP mice.  (A) Histological changes in the thickness of RGC layer in control
mice (n=5) and MOGTCRxThy1CFP mice (n=5) at day 21. Results represent the mean ± SEM of RGC layer thickness. **P<0.01 and
***P<0.001 between control mice and MOG-specific TCR mice at the same distance from optic nerve head. (B) Multiline OCT, a
Spectralis® HRA + OCT modified by Heidelberg Engineering Inc to allow imaging of CFP-expressing RGC and adapted to comply
with mouse optics with a +25D lens and fitted animal mount. Mouse is ABH strain. (C) OCT images of retina were acquired using a
circular OCT scan surrounding the optic nerve head on (D) day 0 and (E) day 21 of disease induction and RNFL thickness was
calculated. (F) Decrease in RNFL thickness after immunisation of MOGTCRxThy1CFP mice to develop ON (n=10). (G) Correlation
between RGC density (measured using retinal flatmounts) and RNFL thickness (measured using OCT). Results represent the mean
± SEM of RNFL thickness. * P<0.05, **P<0.01, ***P<0.001 compared to control.
doi: 10.1371/journal.pone.0079188.g004
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Figure 5.  cSLO imaging during ON in MOGTCRxThy1CFP mice.  (A) Example of retina before disease induction on day 0 and (B)
after disease induction on day 21. (C) Quantification of mean RNFL thickness by cSLO on day 0 and after ON disease induction at
day 21 and comparison with conventional histology at day 21 (n=8). Images of individual RGC taken over a 30° field of view and a
contrast sensitivity of 80% at (D) day 0 and (E) day 21. RGC survival (yellow) and RGC loss (red) are identifiable. Results represent
the mean ± SEM of RGC density.
doi: 10.1371/journal.pone.0079188.g005
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Figure 6.  Neuroprotection with oxcarbazepine and caspase-2 siRNA in MOGTCRxThy1CFP mice.  (A) MOGTCRxThy1CFP
transgenic mice received the following: optic neuritis control (n=7), 100µl daily dose of vehicle (1:1 PBS and DMSO) (n=7) or 100μl
10mg/kg OXC (dissolved in 1:1 PBS and DMSO) (n=7). Mice were sacrificed on day 21. Eyes were flatmounted and RGC were
counted using stereology software. Results represent mean ± SEM of RGC density. (B) Cross sections of the retina stained with
total caspase-2 and (C) active caspase-2 and both were secondary labelled with Alex Fluor 568 (Red). RGC are shown in green
(arrow), but degenerating RGC with lower CFP expression could be detected (dashed arrow). (D) RNFL thickness after ON
induction and treatment with either nonsense or caspase-2 siRNA. (E) Quantification of RGC density after ON induction and
treatment with either a nonsense (n=7) or caspase-2 siRNA (n=8). Plots show mean ± SEM of RGC density and RNFL thickness.
doi: 10.1371/journal.pone.0079188.g006
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increased survival of RGC after ON in MOGTCRxThy1CFP mice
compared to those treated with control or a vehicle (Figure 6E).
This suggests that inhibition of caspase-2 activation using a
therapeutic siRNA may be a useful approach that could be
useful in the treatment of optic neuritis and other inflammatory
optic neuropathies in humans.
Discussion
Experimental autoimmune encephalomyelitis has been one
of the main animal models to investigate autoimmune function
[6]. Although many uses of EAE have revolved around
inhibiting autoimmunity, the success at treating relapsing-
remitting MS, has moved the focus towards monitoring and
treating progressive MS. The visual pathway is receiving
increased attention as a target tissue to monitor
neurodegeneration in MS because of the potential of OCT as a
method to detect RNFL thinning [23,24]. We therefore
developed a novel ON model of MS, with multiple outcomes
such as electrophysiology, visual sensitivity, cSLO and OCT
that reflects potential outcome measures for use in human
trials. Following pupil dilation the cornea of the eye can show a
transient clouding and it is therefore technically challenging to
perform electrophysiology and ocular OCT and cSLO imaging
at the same time. At the time of these experiments the number
of anaesthetics that the animals could undergo was restricted
and some of the equipment used for functional testing had not
yet been obtained, meaning it was not possible to also obtain
functional readouts on the same animals in this study. Use of
OCT is a faster procedure than performing quantitative cSLO.
This study has highlighted potential different outcomes that can
be applied in future studies. These can be selected such that
they are appropriate for their target. However, even without
additional imaging or other outcomes the model can be used
as a screening tool or having a 3Rs-refined outcome to detect
the influence of transgenesis. We have demonstrated two
therapeutic strategies that can protect against nerve cell loss in
this model. Both these therapeutic strategies could be
developed clinically.
This current study describes a refined model for
immunological and neuroprotection studies, further work may
refine the model more. The model is currently sufficiently
robust to detect the action of therapeutic agents such that the
approach may be directly translated to MS, as optic neuritis is
increasingly been seen as a major target. The disease is
consistently robust and exhibits a high incidence and
consistent severity, which is not always the case in MOG
peptide and Freund’s adjuvant induced disease [28,29].
Furthermore it can also detect classes of neuroprotective
agents that can show to be neuroprotective in longer-term
classical EAE studies [30]. It has previously been found that
housing conditions can influence the incidence of spontaneous
EAE in some myelin-specific T cell receptor transgenic mice
[14]. Therefore, differences in housing conditions may exhibit
subtle influences on disease course. However, the disease
incidence in the double transgenic reported here is consistent
with that reported in disease induced with Bordetella pertussis
toxin in single MOG-specific TCR transgenic mice [11, 17).
This suggests that the protocol defined here will be robust and
translatable to different laboratories.
Although models are developed to simulate aspects of the
human disease, this new model may also offer significant
advantages over existing EAE models (see Table 1). Most
notably, there may be a significant refinement in accordance
with the 3Rs principle of replacement, refinement and reduction
of animals in research. Currently, the EAE induction protocol is
considered to be a severe/substantial, United Kingdom Home
Office procedure and so the introduction of the milder,
MOGTCRxThy1CFP mouse model allows disease processes to
be studied in animals without the necessity of using Freund’s
adjuvant that can cause discomfort and granulomas at the
injection site or the development of weight loss and paralysis
[8]. The current model uses a milder and quicker induction
process that allows one to reduce the number of animals used
in each experiment and the outcomes can be obtained in a
shorter period of time than outcomes using conventional EAE.
Animals are in the experiment for weeks versus weeks to
months for classic EAE experiments [8], with both humane and
economic benefits. The disability in this model is limited to
visual sensory loss, which could occur as part of an EAE
experiment. It is important to stress in this context that sight is
a sense that is not of primary importance to rodents as they
have evolved to be active in the dark and have poor visual
sensitivity. Many laboratory strains of mice such as SJL and
CBA mice have hereditary retinal dystrophy, which does not
affect normal behaviour [31]. As the model has been developed
on the C57BL/6 background, commonly used for the
generation of transgenic mice and readily available from
commercial breeders, this should help the rapid dissemination
and adoption of this model by other groups. Many EAE studies
only use paralysis as a read-out for the assessment of whether
a transgene null mutation or a drug influences disease; this
would be difficult to justify ethically with the availability of
alternatives that are milder and more humane, such as the
model developed here.
Furthermore there are many other merits that justify the use
of this model over existing EAE models, in particular potential
economic benefits. This can be achieved through reduced
costs of labour and monitoring. Animals undergoing EAE
require daily monitoring, particularly during periods of paralysis,
to ensure humane endpoints are adequately monitored [8]. In
addition there may be benefit in animal husbandry costs
through a reduction in numbers of animals used or by a
reduction in the time in procedure, which may be twice as long
to monitor neuroprotective treatments [8]. One advantage of
using EAE is that it has an easily visualised neurological
problem that varies and can be monitored over time. However,
the neurological outcomes are typically based on subjective,
often observer-dependent, non-linear and non-parametric
neurological scales that require a large number of observations
to achieve statistical power, compared to objective parametric
outcomes that are observer-independent. Furthermore analysis
of EAE often uses single point-in-time analysis following
terminal procedures/killing of animals and costly and time-
consuming histology, which is again subjective and semi-
quantitative focusing on a few select areas of the CNS. This
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new ON model allows non-lethal, serial and relatively quick
monitoring of clinically-relevant, quantitative outcome
measures that will enable fewer animals to be used.
Whilst this model can be applied to the assessment of
immune function and neurorepair strategies using drugs or
other transgenic or knockout mice, we have shown that it can
also be used to examine neuroprotective strategies, an area of
unmet clinical need in MS. The mechanisms of neuronal
damage in multiple sclerosis and EAE are varied and results
from direct attack and the influence of the inflammatory
penumbra that occurs during active inflammation. This appears
to condition a neurodegenerative environment associated with
Table 1. Comparison of classical EAE with the novel optic
neuritis model.a
 Classical EAE Optic Neuritis Model
Induction Protocol
(REFINEMENT) Uses Freund’s adjuvant Avoids Freund’s adjuvant
Disease severity
(REFINEMENT) Paralytic disease Non-paralytic disease
 Additional signs present No additional signs present
 Long time in procedure Less time in procedure
 SUBSTANTIAL/SEVEREprocedure
MODERATE/MILD
procedure
Outcome measures
(REFINEMENT
AND REDUCTION)
Subjective outcomes Objective outcomes
 Non-parametric statistics Parametric statistics (morepower)
 Lethal outcome measures Non-lethal outcomemeasures
 One-time point histological Repeated serial assessmentin vivo
 Outcome requires culling Group size reductions
Application Immunosuppressive agents Immunosuppressive agents
 Neuroprotective agents Neuroprotective agents
 Neurorepair agents(histology)
Neurorepair agents
(electrophysiology)
Speed Results in 3-4 weeks(immunosuppression) Results in 2-3 weeks
 Results in 2-3 months(Neuroprotection)  
 Analysis in days/weeks Analysis in minutes/hours
 Histological analysis in weeks  
Consumable costs Animal costs for 2-3 months Animal costs for 2-3 weeks
 High recurrent costs Lower recurrent costs
Human costs
Weekdays, weekends and
bank holidays checking
animals
1-2 hours a day extra free,
free weekends and bank
holidays
Solid science Non-parametric outcomes Parametric outcomes
 Histological outcomes Non-histological outcomes
 Observer influence Observer- independent
  Human relevant outcomes
aRefinement and reduction opportunities, economic benefits and application of the
novel optic neuritis model in comparison to classical EAE.
doi: 10.1371/journal.pone.0079188.t001
glial-driven inflammation, neural metabolic failures, which no
longer responds to peripheral immunosuppression both in MS
and in progressive EAE [32,33]. In this current model damage
is generated from the inflammatory penumbra and can model
events in MS. Sodium channel blockade with OXC was found
to be neuroprotective and prevented the RGC loss. The
mechanism of neuroprotection is unlikely to be due to lymphoid
cell immunosuppression based on our results of using sodium
channel blockers in EAE [20]. Neuroprotection with OXC is
most likely to occur at the level of the axon or nerve, or
perhaps through an inhibition of microglial activity, which are
probably central to the pathogenesis of progressive MS, as has
been discussed extensively elsewhere [26,30] as these doses
of drug are not T cell immunosuppressive such that they
prevent disease developing [33]. However, in progressive
disease additional benefit may be achieved through limitation
of sodium loading in nerves, particularly demyelinated nerves
that can lead to excitotoxicity and calcium induced apoptosis
[32]. We aim to translate these animal studies into optic neuritis
MS, where a similar inflammatory penumbra develops.
Because of the ability to induce demyelination and to image the
fate of individual nerve cells, future studies will be able to
monitor whether a slow neurodegeneration of demyelinated
nerves, resembling progressive MS develops. There we have
found that sodium channel blockage appears to be
neuroprotective in drug compliant people with secondary
progressive MS, supporting the translatability from EAE
[34,35]. Biomarker report from the phase II lamotrigine trial in
secondary progressive MS-neurofilament as a surrogate of
disease progression [35]. These results provide promising
evidence to support sodium channel blockers as a
neuroprotective agent in optic neuritis and MS.
Although the first large scale clinical trial of a sodium channel
blocker, Lamotrigine, in MS failed to show any significant
benefit [36]. A main reason for the failure of the trial was the
inability of MRI as primary outcome measure to effectively
detect axonal damage and neuronal loss, which was masked
by drug-induced pseudoatrophy [37]. Another reason is that the
wrong cohort of people with MS was studied. This trial enrolled
people with advanced secondary progressive disease and who
would have already lost much of their compensatory pool of
axons, such that inhibition of salutatory conduction led to poor
tolerance of the drug and non-adherence [36]. Slow
progression of neurodegeneration that is independent of
inhibition of autoimmunity can be modelled in EAE [9,38], but
most EAE paradigms are more reflective of neurodegeneration
driven by active inflammation. Whilst further studies are
required to determine the long-term fate of demyelinated
axons, it is possible to translate the current findings from this
mouse model towards the treatment of human disease, such
as acute ON in MS. Indeed the development work obtained
during this project has helped inform the development of a
novel trial design that we developed for the use of a sodium
channel blocker in acute ON (NCT01451593).
ON is frequently associated with MS and often precedes
other neurologic deficits associated with MS [1]. Although the
majority of people with MS experience persistent visual defects
following ON, gross visual acuity as measured with a Snellen
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chart typically returns to normal and therefore people may be
more reluctant to undergo intra-ocular injection as proof of
principle for the development of siRNA approaches. However,
frequent intra-ocular injections are generally well tolerated by
people with diseases such as macular degeneration.
Neuromyelitis optica/Devic’s disease is an autoimmune
disease involving the spinal cord and optic nerve that is
associated with autoantibodies against aquaporin-4 [39] and
interestingly antibodies against MOG [40]. ON attacks occur in
neuromyelitis optica, but they result in significantly worse visual
outcome than MS and the majority of people will show some
visual loss and risk the development of blindness [39,41]. As
such this novel siRNA-based approach could be developed
towards the treatment of neuromyelitis optica, where people
may be more willing to have invasive treatments directed
towards the eye. This use of siRNA holds potential as a novel
therapeutic approach to treating ON and demonstrates that it is
possible to induce a functional knock-down in the visual
pathway as was found previously following optic nerve crush
[20]. This route of delivery provides a powerful approach to
neurobiology such that it may be possible to explore the local
knock-down of proteins that would otherwise be lethal in global
knockout mice. Currently there are a number of siRNA-based
drugs in the pipeline for human use, including the siRNA to
caspase 2 (QPI-1007) used in this study. Whilst optic neuritis in
multiple sclerosis may not be the major first indication because
in general sight returns, however this could be examined in
Devics MS or neuromyelitis optica associated with the
development of aquaporin-4 and also MOG-specific antibodies
where blindness is the usual outcome. Therefore a sight saving
treatment may be considered and is currently being explored.
In summary, the generation and use of the
MOGTCRxThy1CFP model has many implications for the work
undertaken in this field of experimental neuroscience research
and the development of drugs for people with MS. This new
model provides a more humane and rapid screening tool for
the translation of treatments for neuroimmunological diseases
and has demonstrated the potential of two neuroprotective
therapies.
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